Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals
AIDS, Volume 17, No. 1, Year 2003
Notification
URL copied to clipboard!
Description
Background: Tenofovir is a novel nucleotide analogue recommended for use in HIV-1 infected treatment-experienced patients. Recent data suggest an effect on Hepatitis B virus (HBV) replication. We therefore investigated the use of tenofovir in HIV-1 and HBV co-infected individuals. Methods: Twenty HIV-1/HBV co-infected patients with a median of 108 weeks lamivudine experience (range, 0-270 weeks) received tenofovir 245 mg daily in addition to or as part of their combination antiretroviral therapy. Their immunologic parameters and HIV-1 RNA and HBV DNA viral loads were followed over a period of 52 weeks. In addition, their HBV DNA polymerase was sequenced at baseline to measure the frequency of YMDD mutations that are associated with lamivudine resistance. Findings: A significant decrease in HBV DNA viral load (4 × log10) and alanine aminotransferase levels was observed. There were no significant overall differences between the lamivudine-experienced (n = 15) and -naive (n = 5) individuals and tenofovir was well tolerated. Five patients (25%) underwent HBe antigen seroconversion during the study period. Out of the 15 lamivudine-experienced individuals, 10 had YMDD mutations and one had YIDD mutations in HBV DNA. Interpretation: These results indicate that 52 weeks of tenofovir in addition to antiretroviral therapy is active against HBV, and it appears to overcome lamivudine resistance. © 2003 Lippincott Williams & Wilkins.
Authors & Co-Authors
Nelson, Mark Richard
United Kingdom, London
Chelsea and Westminster Hospital
Portsmouth, Simon D.
United Kingdom, London
Chelsea and Westminster Hospital
Stebbing, Justin
United Kingdom, London
Chelsea and Westminster Hospital
Atkins, Mark C.
United Kingdom, London
Chelsea and Westminster Hospital
Matthews, Gail V.
United Kingdom, London
Chelsea and Westminster Hospital
Morris, Lynn G.
United Kingdom, London
Public Health England
Fisher, Martin J.
United Kingdom, Brighton
Royal Sussex County Hospital
Bower, Mark D.
United Kingdom, London
Chelsea and Westminster Hospital
Gazzard, Brian George L.
United Kingdom, London
Chelsea and Westminster Hospital
Statistics
Citations: 163
Authors: 9
Affiliations: 3
Identifiers
Doi:
10.1097/00002030-200301030-00002
ISSN:
02699370
Research Areas
Genetics And Genomics
Infectious Diseases